A clinical update on the use of resolute stents with dual anti-platelet therapy interruption. (October 2014)

• Record Type: Journal Article
• Authors: O'Mahony, Constantinos; Rothman, Martin; Mathur, Anthony
• Is Part Of: Interventional cardiology. Volume 6:Number 5(2014)
• Page Start: 453
• Page End: 462
• Publication Date: 2014-10
• Subjects: aspirin -- clopidogrel -- dual anti-platelet therapy -- percutaneous coronary intervention -- Resolute zotarolimus-eluting stent -- stent -- stent thrombosis; Cardiology -- Periodicals; Coronary heart disease -- Treatment -- Periodicals; 616.1205
• DOI: 10.2217/ica.14.47
• Languages: English
• ISSNs: 1755-5310

Abstract

Percutaneous coronary intervention is currently the most commonly used revascularization procedure. This success is a direct consequence of the improved medium- and long-term target vessel patency achieved with drug-eluting stents (DES). However, DES are associated with stent thrombosis (ST), a rare but potentially catastrophic complication. Early interruption of dual anti-platelet therapy (DAPT) is a major risk factor for ST and guidelines recommend a minimum duration of DAPT of 6 to 12 months post implantation. Recently published observational data suggest that premature DAPT interruption is not associated with ST in patients treated with the second-generation Resolute zotarolimus-eluting stent. This article reviews the background to the development of Resolute DES and reviews recently published data on ST and DAPT interruption.